Abstract:BackgroundCardiovascular disease remains a major health care challenge. The knowledge about the underlying mechanisms of the respective vascular disease etiologies has greatly expanded over the last decades. This includes the contribution of microRNAs, endogenous non-coding RNA molecules, known to vastly influence gene expression. In addition, short interference RNA has been established as a mechanism to temporarily affect gene expression. This review discusses challenges relating to the design of a RNA interference therapy strategy for the modulation of vascular disease. Despite advances in medical and surgical therapies, atherosclerosis (ATH), aortic aneurysms (AA) are still associated with high morbidity and mortality. In addition, intimal hyperplasia (IH) remains a leading cause of late vein and prosthetic bypass graft failure. Pathomechanisms of all three entities include activation of endothelial cells (EC) and dedifferentiation of vascular smooth muscle cells (VSMC). RNA interference represents a promising technology that may be utilized to silence genes contributing to ATH, AA or IH. Successful RNAi delivery to the vessel wall faces multiple obstacles. These include the challenge of cell specific, targeted delivery of RNAi, anatomical barriers such as basal membrane, elastic laminae in arterial walls, multiple layers of VSMC, as well as adventitial tissues. Another major decision point is the route of delivery and potential methods of transfection. A plethora of transfection reagents and adjuncts have been described with varying efficacies and side effects. Timing and duration of RNAi therapy as well as target gene choice are further relevant aspects that need to be addressed in a temporo-spatial fashion.ConclusionsWhile multiple preclinical studies reported encouraging results of RNAi delivery to the vascular wall, it remains to be seen if a single target can be sufficient to the achieve clinically desirable changes in the injured vascular wall in humans. It might be necessary to achieve simultaneous and/or sequential silencing of multiple, synergistically acting target genes. Some advances in cell specific RNAi delivery have been made, but a reliable vascular cell specific transfection strategy is still missing. Also, off-target effects of RNAi and unwanted effects of transfection agents on gene expression are challenges to be addressed. Close collaborative efforts between clinicians, geneticists, biologists, and chemical and medical engineers will be needed to provide tailored therapeutics for the various types of vascular diseases.

Non‐coding RNAs to treat vascular smooth muscle cell dysfunction

Non-coding RNAs: key regulators of smooth muscle cell fate in vascular disease

Dedifferentiation of Vascular Smooth Muscle Cells Upon Vessel Injury

Noncoding RNAs in Vascular Diseases

Long Non-Coding RNA Regulation of Epigenetics in Vascular Cells

RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations

Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease

Noncoding RNAs in atherosclerosis: regulation and therapeutic potential

Long Noncoding RNA Function in Smooth Muscle Cell Plasticity and Atherosclerosis

Targeting noncoding RNAs to treat atherosclerosis

Long non-coding RNAs: Modulators of phenotypic transformation in vascular smooth muscle cells

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease

Regulatory RNAs Controlling Vascular (dys)function by Affecting TGF-ß Family Signalling.

The Role of Long Non-Coding RNAs in Vascular Smooth Muscle Cell Phenotype and the Pathogenesis of Cardiovascular and Cerebrovascular Aneurysms

From Molecules to Heart Regeneration: Understanding the Complex and Profound Role of Non-Coding RNAs in Stimulating Cardiomyocyte Proliferation for Cardiac Repair

Emerging Role of Exosome-Mediated Intercellular Communication in Vascular Remodeling

Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus

Extracellular Non-Coding RNAs in Cardiovascular Diseases

Non-coding RNAs in cardiac regeneration: Mechanism of action and therapeutic potential

Non-coding RNAs as Epigenetic Gene Regulators in Cardiovascular Diseases

Non‐coding RNAs in Cardiomyocyte Proliferation and Cardiac Regeneration: Dissecting Their Therapeutic Values